Description
Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.
Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!
Faculty
- Sven Francque (Moderator)
- Willem Pieter Brouwer (Faculty)
- Cyrielle Caussy (Faculty)
- Dimitris Papamargaritis (Faculty)
This episode is scheduled following the United Kingdom’s National Obesity Awareness Week.
Related episodes:
- EASL Studio S5E7: Why bother with diet and exercise when an injection will suffice?
- EASL Studio S4E8: The central role of alcohol and food policies on liver health
- EASL Studio S2E2: Fats or carbs, who is the real villain?
ℹ️ Please click here to access the podcast version of this EASL Studio episode.